Navarro RF

Language: Spanish
References: 19
Page: 122-126
PDF size: 114.72 Kb.

ABSTRACT

Chronic obstructive pulmonary disease (COPD) affects approximately 600 million people around the world, 2.7 million die every year, and globally it represents the fourth cause of death, although a preventable one. The annual $ 1, 876 to 2, 000 US dollars cost of the disease and the money spent during an exacerbation can represent a catastrophic expense for the family and society; this makes the ambulatory treatment of COPD of the outmost importance. In this prospective, longitudinal, observational and descriptive study, we analyzed the cost, number of exacerbations and hospitalizations of three groups of out-patients: group I, 32 patients, inhaled salbutamol+ipratropium; group II, 33 patients, inhaled salbutamol+tiotropium; group III, 15 patients, oral teophylline. The analysis showed that group II was the least costly and with the lowest number of disease exacerbations and hospitalizations.

REFERENCES

1. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012.

2. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.

3. Sherk PA, Grossman RF. The chronic obstructive pulmonary disease exacerbation. Clin Chest Med 2000;21:705-721.

4. American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD. www.thoracic.org/copd

5. GOLD. Global strategy for the diagnosis and management, and prevention of chronic obstructive pulmonary disease. www.goldcopd/com/wr.html

6. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costes de la bronquitis crónica y de la EPOC. Estudio de seguimiento de un año. Chest 2003;123:784-791.

7. Faulkner MA, Gisbert R. The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2002;3:219-228.

8. Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract 1998;18:125-133.

9. Hansel TT, Barnes PJ. An Atlas of Chronic Obstructive Pulmonary Disease. COPD. NY: Parthenon Publishing, London; 2004.p.159.

10. 10.Norman MDL. Chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:462-465.

11. 11.O’Donnell DF, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840.

12. 12.Frenk-MJ. La transición de la atención a la salud. Una perspectiva internacional. Fundación Mexicana para la Salud. México: Panamericana;1995. p. 67-73.

13. 13.Kirby L, Vale L. Dialysis for end-stage renal disease. Determining a cost-effective approach. Int J Technol Assess Health Care 2001;17:181-189.

14. 14.Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998;92: 4047-4052.

15. 15.Luce BR, Manning WG, Siegel JE, et al. Estimating cost and cost in cost-effectiveness analysis. In: Health and medicine. NY: Oxford University Press; 1996.p.87-116.

16. 16.Shnoebelen S. Integrating on advanced cost management system into operating systems. NY: McGraw-Hill;1998.p. 67-90.

17. 17.Bruns Jr W, McKinnon S. Information and managers: A field study. J Manag Account Res 1993;5:86-108.

18. 18.Wesitein CM, Statson WB. Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 1997;296:716-721.

19. 19.Vázquez JC. Costos. México: Aguilar, Alfaguara;1998.